Comparison of the dynamics of resistance-associated mutations to nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors after cessation of antiretroviral combination therapy

Antimicrob Agents Chemother. 2004 Feb;48(2):644-7. doi: 10.1128/AAC.48.2.644-647.2004.

Abstract

The dynamics of mutations associated with resistance to antiretroviral drugs were analyzed after cessation of therapy. The results showed that the kinetics of the shift to wild-type amino acid residues were significantly faster for protease inhibitors, intermediate for nonnucleoside reverse transcriptase inhibitors, and slower for nucleoside reverse transcriptase inhibitors.

Publication types

  • Clinical Trial
  • Comparative Study

MeSH terms

  • Anti-HIV Agents / pharmacology*
  • Antiretroviral Therapy, Highly Active*
  • Drug Resistance, Viral
  • Genotype
  • HIV Infections / drug therapy
  • HIV Infections / virology
  • HIV Protease Inhibitors / pharmacology*
  • HIV Reverse Transcriptase / antagonists & inhibitors
  • HIV-1 / drug effects*
  • HIV-1 / genetics*
  • Humans
  • Mutation / genetics*
  • Nucleosides / pharmacology*
  • Proportional Hazards Models
  • Prospective Studies
  • RNA, Viral / genetics
  • Reverse Transcriptase Inhibitors / pharmacology*

Substances

  • Anti-HIV Agents
  • HIV Protease Inhibitors
  • Nucleosides
  • RNA, Viral
  • Reverse Transcriptase Inhibitors
  • HIV Reverse Transcriptase